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Background:
DAX-1 is an orphan nuclear receptor which has been implicated in Dosage-
sensitive sex reversal, Adrenal hypoplasia congenita on the X chromosome gene 1
as well as its role in various cancers. This nuclear receptor has no known ligand, 
lacks typical domains that allow direct binding to DNA, and instead have alanine 
and glycine reach repeats with motifs typically found in coactivators and 
corepressors. 
Prostate cancers have been traditionally diagnosed with bone metastases at 
which point the cancer has advanced rather significantly. Metastasis occurs when 
the cancer cells are able to detach and assume a mesenchymal state. These cells 
can also undergo a process called epithelial mesenchymal transition to traverse cell 
linings into different tissues. This can occur with a loss of proteins such as E-
cadherin, a protein responsible for cell adhesion. Its expression is decreased by 
TWIST and SLUG proteins. RUNX2 on the other hand plays a crucial role in the 
formation of osteoblastic metastases. 
z
Figure 2
Relevant receptor genes and products given the metribolone treatments in LnCap
and LCR1 cell lines. PCR (top), qPCR (middle), and western blot (bottom) analyses 
performed for the various protein targets. GAPDH serves as a control for 
comparison given the treatments.
A. LnCap cell work: PCR analysis reveals presence of all three targets and the 
upregulation of DAX-1 with treatments. qPCR analysis shows the changes in AR and 
DAX-1 to be significant in the metribolone treated samples. Western blot shows 
presence of target proteins with the upregulation of DAX-1 taking effect. 
B. LCR1 cell work :PCR analysis  here instead shows a distinct lack of DAX-1 thanks 
to the CRISPR knockout. qPCR analysis shows the significant decrease in AR and lack 
of DAX-1 across the cell line. Western blot shows presence of target proteins with 
the entire lack of DAX-1 protein.
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Figure 3
Metastatic genes and products given the metribolone treatments in both cell lines. 
PCR (top), qPCR (middle), and western blot (bottom) analyses performed for the 
various protein targets. GAPDH serves as a control for comparison given the 
treatments.
A. LnCap cell work: PCR show effects of metribolone on TWIST and SLUG and no 
effect on RUNX2. qPCR identifies significant changes in all three but mainly in 
TWIST expression. Western blot analysis shows an increase in DAX-1 protein 
production with the increasing metribolone treatments and SLUG expression. 
B. LCR1 cell work: PCR show increase of RUNX2 in higher doses and no effect on 
TWIST and SLUG. qPCR identifies significant changes in all three but mainly in 
RUNX2 expression again. Western blot analysis shows an increase in DAX-1 protein 
production with the increasing metribolone treatments and no SLUG expression 
change in the absence of DAX-1.
Conclusion
DAX-1 shows a significant influence over the metastasis related proteins and is 
therefore a potential target for therapies given its role in repressing the metastatic 
changes. We see that in LnCap cells, the metribolone is able to upregulate DAX-1. 
This can be associated with the relevant changes in the protein targets TWIST, 
SLUG, and RUNX2. These changes can be attributed to DAX-1 working in 
conjunction with activated androgen receptors due to the fact that LCR1 cells seem 
to be unresponsive to the metribolone treatments. A key difference is found in 
DAX-1 expression which seems to decrease TWIST and SLUG expression but RUNX2 
seems to require some other factor given its expression at high metribolone 
dosages. Further western blot analysis is required to complete this work.
Figure 1 Basic putative mechanism of metribolone (MB) treatments with 
androgen receptor (AR) and the effects with DAX-1. DAX-1 is suspected to 
influence the following proteins involved in metastasis: SLUG, TWIST, and RUNX2; 
labeled by three asterisks.
Introduction:
Metastatic marker interactions with DAX-1 are of interest given prostate 
cancers progressions. DAX-1 has been shown to be expressed in LnCap cells but 
not in LCR1 cells as shown in Figure 2. The LCR1 cell line is a CRISPR knockout of 
DAX-1 so that it is not expressed in the cells. The figure shows the results of the 
CRISPR knockout to be significantly successful and the presence of androgen 
receptor in both cell lines.
Due to the fact that LCR1 doesn’t express DAX-1 innately, the effects caused 
by metribolone observed will be identify key roles DAX-1 is involved in. From 
previous research in the lab some influenced targets have been identified in 
proliferation, apoptosis, and metastasis to hone in particular factors. Identifying 
these targets individually characterize the influence DAX-1 has on metastatic 
processes. 
